Paula Carpintero-Fernández

This paper identifies Cx43 as a target that enhances CDK4/6 inhibitor efficacy and promotes elimination of therapy-induced senescent tumor cells through senolytic agents.

This study shows that Cx43 enhances the effectiveness of BRAF/MEKi by reducing DNA repair, leading to increased DNA damage and cellular senescence, and proposes a novel therapeutic approach using sEVs.